Works by Gooderham, Melinda

Results: 143
    1
    2
    3

    The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.

    Published in:
    Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-53384-1
    By:
    • Silverberg, Jonathan I.;
    • Rosmarin, David;
    • Chovatiya, Raj;
    • Bieber, Thomas;
    • Schleicher, Stephen;
    • Beck, Lisa;
    • Gooderham, Melinda;
    • Chaudhry, Sohail;
    • Fanton, Christie;
    • Yu, Danni;
    • Levy, Joshua;
    • Liu, Yi;
    • Miyazaki, Takahiro;
    • Tagliaferri, Mary;
    • Schmitz, Carsten;
    • Nirula, Ajay;
    • Kotzin, Brian;
    • Zalevsky, Jonathan
    Publication type:
    Article
    4
    5

    Considerations for defining and diagnosing generalized pustular psoriasis.

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2025, v. 39, n. 3, p. 487, doi. 10.1111/jdv.20310
    By:
    • Prajapati, Vimal H.;
    • Lynde, Charles W.;
    • Gooderham, Melinda J.;
    • Hong, H. Chih‐ho;
    • Kirchhof, Mark G.;
    • Lansang, Perla;
    • Ringuet, Julien;
    • Turchin, Irina;
    • Vender, Ron;
    • Yeung, Jensen;
    • Papp, Kim A.
    Publication type:
    Article
    6

    Combining treat‐to‐target principles and shared decision‐making: International expert consensus‐based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis.

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 11, p. 2139, doi. 10.1111/jdv.20229
    By:
    • Silverberg, Jonathan I.;
    • Gooderham, Melinda;
    • Katoh, Norito;
    • Aoki, Valeria;
    • Pink, Andrew E.;
    • Binamer, Yousef;
    • Rademaker, Marius;
    • Fomina, Daria;
    • Gutermuth, Jan;
    • Ahn, Jiyoung;
    • Valenzuela, Fernando;
    • Ameen, Mahreen;
    • Steinhoff, Martin;
    • Kirchhof, Mark G.;
    • Lio, Peter;
    • Wollenberg, Andreas
    Publication type:
    Article
    7
    8

    Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 5, p. 864, doi. 10.1111/jdv.19748
    By:
    • Strober, Bruce;
    • Bachelez, Hervé;
    • Crowley, Jeffrey;
    • Elewski, Boni E.;
    • Gooderham, Melinda;
    • Menter, Alan;
    • Strohal, Robert;
    • Chen, Michael M.;
    • Wu, Tianshuang;
    • Zhan, Tianyu;
    • Photowala, Huzefa;
    • Armstrong, April
    Publication type:
    Article
    9

    Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 2, p. 340, doi. 10.1111/jdv.19500
    By:
    • Eyerich, Kilian;
    • Gooderham, Melinda J.;
    • Silvestre, Juan Francisco;
    • Shumack, Stephen P.;
    • Mendes‐Bastos, Pedro;
    • Aoki, Valeria;
    • Ortoncelli, Michela;
    • Silverberg, Jonathan I.;
    • Teixeira, Henrique D.;
    • Chen, Shirley H.;
    • Calimlim, Brian M.;
    • Takemoto, Shunya;
    • Sancho, Cristina;
    • Fritz, Björn;
    • Irvine, Alan D.
    Publication type:
    Article
    10
    11
    12

    Canadian Consensus Guidelines for the Management of Vitiligo.

    Published in:
    Dermatology & Therapy, 2025, v. 15, n. 6, p. 1351, doi. 10.1007/s13555-025-01402-5
    By:
    • Prajapati, Vimal H.;
    • Lui, Harvey;
    • Miller-Monthrope, Yvette;
    • Ringuet, Julien;
    • Turchin, Irina;
    • Hong, H. Chih-ho;
    • Lynde, Charles;
    • Papp, Kim A.;
    • Yeung, Jensen;
    • Gooderham, Melinda J.
    Publication type:
    Article
    13
    14
    15
    16

    A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.

    Published in:
    Dermatology & Therapy, 2024, v. 14, n. 10, p. 2877, doi. 10.1007/s13555-024-01268-z
    By:
    • Alexis, Andrew F.;
    • Gooderham, Melinda;
    • Kwatra, Shawn G.;
    • Amin, Ahmad;
    • Taylor, Susan;
    • Espaillat, Ramon;
    • Rettig, Trisha;
    • Wu, Tianshuang;
    • Shi, Linyu;
    • Kaldas, Mark I.;
    • Dilley, Deanne M.;
    • Sinvhal, Ranjeeta;
    • Nduaka, Chudy;
    • Lockshin, Benjamin
    Publication type:
    Article
    17
    18
    19
    20

    Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.

    Published in:
    Dermatology & Therapy, 2024, v. 14, n. 5, p. 1145, doi. 10.1007/s13555-024-01158-4
    By:
    • Simpson, Eric L.;
    • de Bruin-Weller, Marjolein;
    • Hong, H. Chih-ho;
    • Staumont-Sallé, Delphine;
    • Blauvelt, Andrew;
    • Eyerich, Kilian;
    • Gooderham, Melinda;
    • Shahriari, Mona;
    • Mallbris, Lotus;
    • Atwater, Amber Reck;
    • Rueda, Maria Jose;
    • Ding, Yuxin;
    • Liu, Zhuqing;
    • Agell, Helena;
    • Silverberg, Jonathan I.
    Publication type:
    Article
    21

    Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.

    Published in:
    Dermatology & Therapy, 2024, v. 14, n. 5, p. 1211, doi. 10.1007/s13555-024-01155-7
    By:
    • Kircik, Leon H.;
    • Stein Gold, Linda;
    • Gold, Michael;
    • Weiss, Jonathan S.;
    • Harper, Julie C.;
    • Del Rosso, James Q.;
    • Bunick, Christopher G.;
    • Bhatia, Neal;
    • Tanghetti, Emil A.;
    • Eichenfield, Lawrence F.;
    • Baldwin, Hilary;
    • Draelos, Zoe D.;
    • Callender, Valerie D.;
    • Han, George;
    • Gooderham, Melinda J.;
    • Sadick, Neil;
    • Lupo, Mary P.;
    • Lain, Edward;
    • Werschler, William Philip
    Publication type:
    Article
    22
    23
    24
    25
    26
    27

    Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.

    Published in:
    Dermatology & Therapy, 2023, v. 13, n. 4, p. 867, doi. 10.1007/s13555-023-00905-3
    By:
    • Papp, Kim A.;
    • Melosky, Barbara;
    • Sehdev, Sandeep;
    • Hotte, Sebastien J.;
    • Beecker, Jennifer R.;
    • Kirchhof, Mark G.;
    • Turchin, Irina;
    • Dutz, Jan P.;
    • Gooderham, Melinda J.;
    • Gniadecki, Robert;
    • Hong, Chih-ho;
    • Lambert, Jo;
    • Lynde, Charles W.;
    • Prajapati, Vimal H.;
    • Vender, Ronald B.
    Publication type:
    Article
    28
    29
    30

    Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.

    Published in:
    Dermatology & Therapy, 2023, v. 13, n. 1, p. 269, doi. 10.1007/s13555-022-00849-0
    By:
    • Papp, Kim A.;
    • Gooderham, Melinda;
    • Dei-Cas, Ignacio;
    • LopezTello, Adriana;
    • Garcia-Rodriguez, Juan C.;
    • Taveras, Carmen Yris;
    • Rousselin, Azucena Hernández;
    • Lavieri, Alberto;
    • Maiolino, Mónica;
    • Quintero, Delfina Guadalupe Villanueva;
    • Rihakova, Lenka;
    • Salibe, Mariano;
    • Pertuz, Wilfran
    Publication type:
    Article
    31
    32
    33
    34

    Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.

    Published in:
    Dermatology & Therapy, 2022, v. 12, n. 5, p. 1073, doi. 10.1007/s13555-022-00722-0
    By:
    • Papp, Kim A.;
    • Beecker, Jennifer;
    • Cooper, Curtis;
    • Kirchhof, Mark G.;
    • Pozniak, Anton L.;
    • Rockstroh, Juergen K.;
    • Dutz, Jan P.;
    • Gooderham, Melinda J.;
    • Gniadecki, Robert;
    • Hong, Chih-ho;
    • Lynde, Charles W.;
    • Maari, Catherine;
    • Poulin, Yves;
    • Vender, Ronald B.;
    • Walmsley, Sharon L.
    Publication type:
    Article
    35
    36

    Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

    Published in:
    Dermatology & Therapy, 2022, v. 12, n. 2, p. 495, doi. 10.1007/s13555-021-00649-y
    By:
    • Thaçi, Diamant;
    • Strober, Bruce;
    • Gordon, Kenneth B.;
    • Foley, Peter;
    • Gooderham, Melinda;
    • Morita, Akimichi;
    • Papp, Kim A.;
    • Puig, Lluís;
    • Menter, M. Alan;
    • Colombo, Matthew J.;
    • Elbez, Yedid;
    • Kisa, Renata M.;
    • Ye, June;
    • Napoli, Andrew A.;
    • Wei, Lan;
    • Banerjee, Subhashis;
    • Merola, Joseph F.;
    • Gottlieb, Alice B.
    Publication type:
    Article
    37
    38

    Practical Management of Patients with Atopic Dermatitis on Dupilumab.

    Published in:
    Dermatology & Therapy, 2021, v. 11, n. 5, p. 1805, doi. 10.1007/s13555-021-00586-w
    By:
    • Papp, Kim A.;
    • Hong, Chih-ho;
    • Lansang, M. Perla;
    • Turchin, Irina;
    • Adam, David N.;
    • Beecker, Jennifer R.;
    • Bissonnette, Robert;
    • Gooderham, Melinda J.;
    • Jack, Carolyn;
    • Joseph, Marissa;
    • Lynde, Charles W.;
    • Shear, Neil H.
    Publication type:
    Article
    39
    40
    41

    Psoriasis Prevalence and Severity by Expert Elicitation.

    Published in:
    Dermatology & Therapy, 2021, v. 11, n. 3, p. 1053, doi. 10.1007/s13555-021-00518-8
    By:
    • Papp, Kim A.;
    • Gniadecki, Robert;
    • Beecker, Jennifer;
    • Dutz, Jan;
    • Gooderham, Melinda J.;
    • Hong, Chih-Ho;
    • Kirchhof, Mark G.;
    • Lynde, Chuck W.;
    • Maari, Catherine;
    • Poulin, Yves;
    • Vender, Ron B.
    Publication type:
    Article
    42

    Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.

    Published in:
    Dermatology & Therapy, 2020, v. 10, n. 3, p. 431, doi. 10.1007/s13555-020-00367-x
    By:
    • Leonardi, Craig;
    • Reich, Kristian;
    • Foley, Peter;
    • Torii, Hideshi;
    • Gerdes, Sascha;
    • Guenther, Lyn;
    • Gooderham, Melinda;
    • Ferris, Laura K.;
    • Griffiths, Christopher E. M.;
    • ElMaraghy, Hany;
    • Crane, Heidi;
    • Patel, Himanshu;
    • Burge, Russel;
    • Gallo, Gaia;
    • Shrom, David;
    • Leung, Ann;
    • Lin, Chen-Yen;
    • Papp, Kim
    Publication type:
    Article
    43

    Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure.

    Published in:
    Dermatology & Therapy, 2020, v. 10, n. 1, p. 133, doi. 10.1007/s13555-019-00340-3
    By:
    • Armstrong, April;
    • Paul, Carle;
    • Puig, Luis;
    • Boehncke, Wolf Henning;
    • Freeman, Michael;
    • Torii, Hideshi;
    • Papp, Kim;
    • Griffiths, Christopher E. M.;
    • Blauvelt, Andrew;
    • Reich, Kristian;
    • Gooderham, Melinda;
    • Terui, Tadashi;
    • Renda, Lisa;
    • Agada, Noah;
    • Xu, Wen;
    • Gallo, Gaia;
    • Lebwohl, Mark G.
    Publication type:
    Article
    44
    45
    46
    47
    48
    49

    Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.

    Published in:
    Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03122-w
    By:
    • Papp, Kim A.;
    • Gooderham, Melinda;
    • Lynde, Charles;
    • Brassard, Danielle;
    • Al-Mohammedi, Faisal;
    • Prajapati, Vimal H.;
    • Delorme, Isabelle;
    • Albrecht, Lorne;
    • Haydey, Richard;
    • Alam, Maryam Shayesteh;
    • Beecker, Jennifer;
    • Siddha, Sanjay;
    • Maguin, Marie;
    • Farag, Mahmoud S.;
    • Vieira, Antonio;
    • Rihakova, Lenka;
    • Langley, Richard G.
    Publication type:
    Article
    50